Innovhem paticipates to HEMOPROVE study, sponsored by AP-HP

by | March 18, 2024

Cette actualité appartient aux catégories suivantes : Uncategorized

HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP.
The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ function. The primary objective of the study is to evaluate the biological activity of Voxelotor on the reduction of intra vascular hemolysis measured by the biomarkers developed by Innovhem.
A new stage in Innovhem’s commitment to fight against Sickle Cell Disease

For more information

Lastest news of Innovhem

Join our team